^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD22 expression

i
Other names: CD22, CD22 Molecule, CD22 Antigen, SIGLEC2, Sialic Acid-Binding Ig-Like Lectin 2, B-Lymphocyte Cell Adhesion Molecule, T-Cell Surface Antigen Leu-14, B-Cell Receptor CD22, SIGLEC-2, BL-CAM, Sialic Acid Binding Ig-Like Lectin 2, Siglec-2
Entrez ID:
Related biomarkers:
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/14/2024
Initiation :
12/28/2022
Primary completion :
07/01/2027
Completion :
07/01/2029
CD19 • CD22
|
CD19 expression • CD22 expression
|
cyclophosphamide • fludarabine IV
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/13/2024
Initiation :
05/08/2019
Primary completion :
02/01/2025
Completion :
02/01/2025
ABL1 • BCR • CD22
|
CD22 positive • CD22 expression
|
Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/06/2024
Initiation :
03/26/2018
Primary completion :
12/01/2025
Completion :
12/31/2040
CD19 • CD22
|
CD19 expression • CD22 expression
|
cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells • cyclophosphamide intravenous
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
06/05/2024
Initiation :
12/12/2014
Primary completion :
04/03/2019
Completion :
06/01/2040
CD22
|
CD22 expression
|
JCAR018 • anti-CD22 CAR T
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/05/2024
Initiation :
05/23/2022
Primary completion :
12/01/2036
Completion :
12/01/2036
CD22
|
CD22 expression
|
cyclophosphamide • JCAR018 • anti-CD22 CAR T
Phase 2
Children's Oncology Group
Recruiting
Last update posted :
05/30/2024
Initiation :
06/19/2017
Primary completion :
03/31/2026
Completion :
03/31/2026
KMT2A • CD22
|
MLL rearrangement • CD22 expression
|
cytarabine • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
Phase 1
University of Pennsylvania
Active, not recruiting
Last update posted :
05/24/2024
Initiation :
09/27/2018
Primary completion :
01/01/2036
Completion :
01/01/2036
CD22
|
CD22 expression
|
CART22 • huCART19
Phase 3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/23/2024
Initiation :
01/22/2007
Primary completion :
09/30/2017
Completion :
03/07/2025
CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO
|
CD22 expression
|
cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • nelarabine • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection
Phase 1/2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
05/15/2024
Initiation :
08/24/2018
Primary completion :
12/31/2025
Completion :
12/31/2025
CD22
|
CD22 expression
|
epratuzumab-cys-tesirine (ADCT-602)
Phase 2
St. Jude Children's Research Hospital
Recruiting
Last update posted :
04/19/2024
Initiation :
05/14/2019
Primary completion :
12/01/2024
Completion :
01/01/2025
CD22
|
CD22 expression
|
cytarabine • methotrexate • Besponsa (inotuzumab ozogamicin) • methylprednisolone sodium succinate
Phase 3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
03/22/2024
Initiation :
10/04/2014
Primary completion :
03/31/2020
Completion :
09/22/2024
CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO
|
CD22 expression
|
cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
Phase 1
Stanford University
Active, not recruiting
Last update posted :
03/07/2024
Initiation :
09/12/2019
Primary completion :
12/30/2024
Completion :
12/30/2037
CD22
|
CD22 positive • CD22 expression • CD20 negative
|
cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • firicabtagene autoleucel (CRG-022)
Phase 1
Crystal Mackall, MD
Active, not recruiting
Last update posted :
02/28/2024
Initiation :
09/01/2017
Primary completion :
09/01/2025
Completion :
09/01/2035
CD19 • CD22
|
CD19 positive • CD19 expression • CD22 expression
|
cyclophosphamide • fludarabine IV • avipendekin pegol (NKTR-255) • cyclophosphamide intravenous
Phase 1
Stanford University
Active, not recruiting
Last update posted :
02/12/2024
Initiation :
01/10/2020
Primary completion :
10/31/2023
Completion :
09/10/2036
CD22
|
CD22 positive • CD22 expression
|
cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • firicabtagene autoleucel (CRG-022)
Phase 3
Charite University, Berlin, Germany
Completed
Last update posted :
02/09/2024
Initiation :
05/01/2014
Primary completion :
07/31/2023
Completion :
07/31/2023
CD22
|
CD22 expression
|
Epratucyn (epratuzumab)
Phase 1
University of Pennsylvania
Recruiting
Last update posted :
02/05/2024
Initiation :
01/13/2016
Primary completion :
12/01/2037
Completion :
12/01/2037
CD22
|
CD22 expression
|
CART22
Phase 1
Baylor College of Medicine
Recruiting
Last update posted :
02/02/2024
Initiation :
07/18/2023
Primary completion :
07/17/2026
Completion :
03/29/2040
CD20 • CD19 • CD22
|
CD19 expression • CD22 expression
|
cyclophosphamide • fludarabine IV • autologous TriCAR T • cyclophosphamide intravenous
Phase 1/2
Stephan Grupp MD PhD
Recruiting
Last update posted :
12/19/2023
Initiation :
01/25/2023
Primary completion :
01/15/2027
Completion :
01/15/2029
CD22
|
CD19 expression • CD22 expression
|
Kymriah (tisagenlecleucel-T) • CART22 • huCART19
Phase 1/2
Institute of Hematology & Blood Diseases Hospit...
Not yet recruiting
Last update posted :
11/02/2023
Initiation :
10/30/2023
Primary completion :
12/30/2024
Completion :
12/30/2025
CD22
|
CD22 expression
|
Venclexta (venetoclax) • Gazyva (obinutuzumab) • Besponsa (inotuzumab ozogamicin) • Epidaza (chidamide)
Phase 1/2
Cellectis S.A.
Recruiting
Last update posted :
09/25/2023
Initiation :
10/14/2019
Primary completion :
12/31/2023
Completion :
01/31/2026
CD22
|
CD22 expression
|
Campath (alemtuzumab) • UCART22
Phase 2
Versailles Hospital
Active, not recruiting
Last update posted :
09/06/2023
Initiation :
12/28/2017
Primary completion :
05/30/2023
Completion :
06/01/2024
ABL1 • BCR • CD22
|
CD22 expression
|
Besponsa (inotuzumab ozogamicin)
Phase 2
University of Chicago
Recruiting
Last update posted :
08/25/2023
Initiation :
03/02/2021
Primary completion :
06/30/2024
Completion :
05/01/2026
ABL1 • BCR • CD22
|
CD22 expression
|
dasatinib • Iclusig (ponatinib) • Besponsa (inotuzumab ozogamicin) • vincristine
Phase 2
Beijing Boren Hospital
Active, not recruiting
Last update posted :
08/02/2023
Initiation :
05/01/2020
Primary completion :
05/01/2024
Completion :
11/01/2024
ABL1 • CD22
|
CD19 expression • CD22 positive • CD22 expression
|
cyclophosphamide
Phase 1
University of Washington
Completed
Last update posted :
07/06/2023
Initiation :
09/24/2019
Primary completion :
10/20/2022
Completion :
06/28/2023
CD22
|
CD22 positive • CD22 expression
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • daunorubicin • cyclophosphamide intravenous
Phase 1/2
Chongqing Precision Biotech Co., Ltd
Recruiting
Last update posted :
04/18/2023
Initiation :
08/25/2020
Primary completion :
12/31/2023
Completion :
07/01/2024
IL6 • CD22 • IL10
|
CD19 expression • CD22 positive • CD22 expression • IL10 elevation
Phase 1/2
Chongqing Precision Biotech Co., Ltd
Recruiting
Last update posted :
04/18/2023
Initiation :
05/23/2021
Primary completion :
12/31/2023
Completion :
07/01/2024
IL6 • CD22 • IL10
|
CD19 expression • CD22 positive • CD22 expression • IL10 elevation
|
CD19 and CD22 targeted prime CAR-T
Phase 1/2
Chongqing Precision Biotech Co., Ltd
Recruiting
Last update posted :
04/18/2023
Initiation :
09/01/2019
Primary completion :
12/31/2023
Completion :
07/01/2024
CD22
|
CD19 expression • CD22 positive • CD22 expression
Phase 1/2
Federal Research Institute of Pediatric Hematol...
Active, not recruiting
Last update posted :
02/22/2023
Initiation :
07/27/2020
Primary completion :
03/13/2022
Completion :
03/13/2027
CD22
|
CD19 expression • CD22 expression
|
cytarabine • cyclophosphamide • etoposide IV • dexamethasone • fludarabine IV • Actemra IV (tocilizumab) • MB-CAR-T19-22
Phase 1
Novartis Pharmaceuticals
Withdrawn
Last update posted :
12/21/2022
Initiation :
01/24/2023
Primary completion :
08/13/2026
Completion :
08/13/2026
CD22
|
CD19 expression • CD22 expression
|
IMJ995
Phase 1/2
Kecellitics Biotech Company Ltd
Not yet recruiting
Last update posted :
12/14/2022
Initiation :
12/10/2022
Primary completion :
12/10/2024
Completion :
12/10/2025
CD22
|
CD19 expression • CD22 expression
|
cyclophosphamide • CD19/CD22 chimeric antigen receptor T cell
Phase 2
Nicola Goekbuget
Recruiting
Last update posted :
11/02/2022
Initiation :
05/02/2018
Primary completion :
06/01/2025
Completion :
12/01/2025
CD22
|
CD22 expression
|
Besponsa (inotuzumab ozogamicin)
Phase N/A
Institute of Hematology & Blood Diseases Hospital
Not yet recruiting
Last update posted :
11/02/2022
Initiation :
10/30/2022
Primary completion :
07/31/2024
Completion :
07/31/2024
ABL1 • BCR • CD22
|
CD22 expression
|
Besponsa (inotuzumab ozogamicin) • Nailike (olverembatinib)
Phase 2
Beijing Boren Hospital
Recruiting
Last update posted :
08/15/2022
Initiation :
05/01/2020
Primary completion :
05/01/2024
Completion :
10/01/2024
ABL1 • CD22
|
CD22 positive • CD22 expression
|
cyclophosphamide • Anti-CD22 CAR-T Cells
Phase 1
Institute of Hematology & Blood Diseases Hospital
Active, not recruiting
Last update posted :
08/03/2022
Initiation :
09/30/2019
Primary completion :
12/01/2023
Completion :
12/01/2023
CD22
|
CD22 expression
|
HY004
Phase 1/2
Autolus Limited
Completed
Last update posted :
02/01/2021
Initiation :
06/26/2017
Primary completion :
05/18/2020
Completion :
05/18/2020
CD22
|
CD19 expression • CD22 expression
|
cyclophosphamide • AUTO3
Phase 1/2
Shenzhen University General Hospital
Recruiting
Last update posted :
01/26/2021
Initiation :
10/20/2020
Primary completion :
12/31/2022
Completion :
12/31/2022
CD19 • CD22
|
CD19 expression • CD22 expression • CD19 underexpression
|
CD19/CD22 dual-target CAR-T
Phase 1
Hebei Yanda Ludaopei Hospital
Not yet recruiting
Last update posted :
06/02/2020
Initiation :
06/01/2020
Primary completion :
12/01/2022
Completion :
12/01/2022
CD22
|
CD22 positive • CD22 expression • CD20 negative
|
GC022F • SENL-B19
Phase 1
Hebei Yanda Ludaopei Hospital
Unknown status
Last update posted :
05/28/2020
Initiation :
10/22/2019
Primary completion :
09/01/2020
Completion :
06/01/2022
CD22
|
CD19 expression • CD22 expression
|
GC022F • SENL-B19
Phase 1/2
Kecellitics Biotech Company Ltd
Unknown status
Last update posted :
12/23/2019
Initiation :
02/01/2020
Primary completion :
07/01/2021
Completion :
07/01/2022
CD22
|
CD22 expression
|
anti-CD22-CAR
Phase 1/2
Southwest Hospital, China
Unknown status
Last update posted :
06/25/2019
Initiation :
10/01/2016
Primary completion :
10/01/2019
Completion :
10/01/2020
CD22
|
CD22 expression